Acceptability of Second-Line Antidepressant Medications Using Filled Prescription Sequences in a Nationwide Cohort Study

Charles Ouazana-Vedrines, MD; Thomas Lesuffleur, MSc; Pierre Denis, MSc; Nicolas Hoertel, MD, PhD; Romain Olekhnovitch, PhD; Mark Olfson, MD, PhD; Carlos Blanco, MD, PhD; Frédéric Limosin, MD, PhD; Antoine Rachas, MD, PhD; Philippe Tuppin, MD, PhD; Cédric Lemogne, MD, PhD

J Clin Psychiatry 2022;83(6):21m14248

ABSTRACT

Background: Although about half of patients do not respond to a first-line antidepressant medication, there is no consensus on the best second-line option. The aim of this nationwide population-based study was to rank antidepressants according to their relative acceptability (ie, efficacy and tolerability) using filled prescription sequences after failure of first treatment.

Methods: About 1.2 million people were identified as new antidepressant users in the French national health data system in 2011. The inclusion criterion was having at least 2 filled prescriptions of a second-line treatment after a filled prescription of a first-line treatment, resulting in 63,726 participants. The outcome was clinical acceptability as measured by the continuation/change ratio for second-line treatment. Continuation sequence was defined as at least 2 refills of the same treatment. Change sequence was defined as at least 1 filled prescription of another antidepressant. Adjusted odds ratios (aORs) were computed through multivariable binary logistic regressions.

Results: Intraclass switch had a better acceptability than interclass switch (aOR [95% CI]: 1.23 [1.20–1.28]). According to the first-line treatment, intraclass switch remained more acceptable for selective serotonin reuptake inhibitors only (1.37 [1.31–1.42]). For α₂ blockers and tricyclic agents, combination antidepressant therapy was the most acceptable second-line option (1.59 [1.27–2.01] and 2.53 [1.53–4.04], respectively), whereas for serotonin-norepinephrine reuptake inhibitors there was no significant difference between the strategies. For other antidepressants, intraclass switch had lower acceptability than interclass switch (0.70 [0.51–0.95]).

Conclusions: Administrative claim databases may help with ranking acceptability of second-line treatments in real world settings and complement randomized controlled trials in informing clinicians about the most acceptable second-line options according to the first-line treatment.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (34)

Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171(4):453–462. PubMed CrossRef
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. PubMed CrossRef
Hoertel N, Franco S, Wall MM, et al. Mental disorders and risk of suicide attempt: a national prospective study. Mol Psychiatry. 2015;20(6):718–726. PubMed CrossRef
Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet. 2016;387(10024):1227–1239. PubMed CrossRef
Depression overview - NICE Pathways. NICE website. https://pathways.nice.org.uk/pathways/depression. 2020.
Traitement par antidépresseurs. ANSM: Agence Nationale de Sécurité du Médicament et des Produits de Santé. 2019. https://archiveansm.integra.fr/Dossiers/Traitements-par-antidepresseurs/Traitement-par-antidepresseurs/(offset)/0
Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. 2010. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
Gabriel FC, de Melo DO, Fráguas R, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS One. 2020;15(4):e0231700. PubMed CrossRef
Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. PubMed CrossRef
Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed CrossRef
Stein MB, Sareen J. Clinical Practice: generalized anxiety disorder. Solomon CG, ed. N Engl J Med. 2015;373(21):2059–2068. >
Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23. PubMed CrossRef
MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23. PubMed CrossRef
Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512–516. PubMed CrossRef
Malhi GS, Bell E, Singh AB, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disord. 2020;22(8):788–804. PubMed CrossRef
Boyce P, Hopwood M, Morris G, et al. Switching antidepressants in the treatment of major depression: when, how and what to switch to? J Affect Disord. 2020;261:160–163. PubMed CrossRef
Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019;12(12):CD010557. PubMed CrossRef
Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry. 2008;69(8):1276–1280. PubMed CrossRef
Franco S, Hoertel N, McMahon K, et al. Generalizability of pharmacologic and psychotherapy clinical trial results for posttraumatic stress disorder to community samples. J Clin Psychiatry. 2016;77(8):e975–e981. PubMed CrossRef
Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials. 2009;6(2):109–118. PubMed CrossRef
Humphreys K, Harris AHS, Weingardt KR. Subject eligibility criteria can substantially influence the results of alcohol-treatment outcome research. J Stud Alcohol Drugs. 2008;69(5):757–764. PubMed CrossRef
Hoertel N, Falissard B, Humphreys K, et al. Do clinical trials of treatment of alcohol dependence adequately enroll participants with co-occurring independent mood and anxiety disorders? an analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2014;75(3):231–237. PubMed CrossRef
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMed CrossRef
Olekhnovitch R, Hoertel N, Limosin F, et al. Using filled prescription sequences to rank antidepressants according to their acceptability in the general population: the Constances cohort. J Psychiatr Res. 2020;123:72–80. PubMed CrossRef
Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962. PubMed CrossRef
Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286–290. PubMed CrossRef
Constantinou P, Tuppin P, Fagot-Campagna A, et al. Two morbidity indices developed in a nationwide population permitted performant outcome-specific severity adjustment. J Clin Epidemiol. 2018;103:60–70. PubMed CrossRef
Verhaak PFM, de Beurs D, Spreeuwenberg P. What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? a longitudinal cohort analysis. BMJ Open. 2019;9(2):e024051. PubMed CrossRef
Hansen DG, Vach W, Rosholm J-U, et al. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract. 2004;21(6):623–629. PubMed CrossRef
Blanco C, Rafful C, Olfson M. The use of clinical trials in comparative effectiveness research on mental health. J Clin Epidemiol. 2013;66(suppl):S29–S36. PubMed CrossRef
Blanco C, Campbell AN, Wall MM, et al. Toward national estimates of effectiveness of treatment for substance use. J Clin Psychiatry. 2017;78(1):e64–e70. PubMed CrossRef
Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370–1372. PubMed CrossRef
Sox HC, Lewis RJ. Pragmatic trials: practical answers to “real world” questions. JAMA. 2016;316(11):1205–1206. PubMed CrossRef
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. PubMed CrossRef